Pharmacy News Article

Actavis Group, the international generic pharmaceuticals company, announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion HCl Extended-Release (SR) tablets 100mg and 200mg. Distribution of the product will commence immediately (see also Bupropion Therapy).

Bupropion HCl SR Tablets, the generic equivalent of Wellbutrin SR by GlaxoSmithKline, are now available from Actavis in the following strengths: 100mg, 150mg, and 200mg. Bupropion HCl SR is used in the treatment of major depressive disorder. Annual U.S. sales of Wellbutrin SR 100mg and 200mg and the generic equivalent in that strength was US$115 million for the 12 months ending March 2010 according to IMS Health data. The addition of the 100mg and 200mg Bupropion HCl SR complements Actavis' already approved and marketed Bupropion HCl SR 150mg. Actavis received approval of Bupropion HCl SR 150mg in March, 2008.